Source disclosure: January 08, 2026
GNI Group Ltd. [2160.T]
TOKYO, Jan 08 (Pulse News Wire) – GNI Group Ltd. (2160.T) announced that its subsidiary, Cullgen Inc., will participate in the 44th Annual J.P.
Morgan Healthcare Conference held in San Francisco from January 12, 2026. The conference attracts investors and executives from around the world.
Additionally, Cullgen released updated corporate presentation materials highlighting several advancements: - A new non-opioid pain medication candidate, CG1,419, is scheduled to begin Phase II clinical trials in Q2 2026. - A novel target development program aimed at inflammatory diseases has been added to the pipeline and is advancing towards IND application preparation.
This participation marks a significant step in Cullgen's ongoing efforts to showcase its latest research and developments to global stakeholders.
AI-translated content. 🟡 Confidence: Standard See terms • Original filing